101,83 €
3,06 % gestern
L&S, 8. Oktober, 22:54 Uhr
ISIN
US89377M1099
Symbol
TMDX
Berichte

TransMedics Group, Inc. Aktie News

Positiv
The Motley Fool
etwa 11 Stunden alt
One great thing about the healthcare sector is that the need for medical services never goes out of style, and in fact, is likely to be in even higher demand in the next decade.
Positiv
Seeking Alpha
16 Tage alt
TransMedics remains a strong buy despite recent pullback, driven by seasonal weakness and changing transplant transport trends. TMDX's next-gen OCS heart and lung devices, along with kidney perfusion development, position TMDX for significant growth and market expansion. International markets, especially Europe, Middle East, and Australia, offer substantial growth opportunities and diversificat...
Neutral
PRNewsWire
17 Tage alt
Modern, purpose-built Mercedez-Benz V-Class fleet to be deployed across four National OCS Program ("NOP") hubs in Italy to support utilization of TransMedics' Organ Care System ("OCS") perfusion technology and increase donor organ utilization for patients in need TransMedics President and Chief Executive Officer, Waleed Hassanein, M.D., to discuss strategic collaboration at upcoming Italian Soc...
Neutral
Seeking Alpha
22 Tage alt
Concerns about seasonal weakness have dragged TransMedics' share price lower in recent weeks. While TransMedics' growth is moderating, there remains a sizeable growth opportunity within just the U.S. liver market. TMDX's next-gen heart and lung programs, kidney device development, and international expansion could also drive significant growth longer term.
Neutral
Seeking Alpha
etwa ein Monat alt
TransMedics Group, Inc. (NASDAQ:TMDX ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 10:00 AM EDT Company Participants Waleed Hassanein - Founder, President, CEO & Director Gerardo Hernandez - CFO & Treasurer Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Presentation Patrick Wood MD of Equity Research Hi, everybody. Welcome and thanks ...
Positiv
Seeking Alpha
etwa ein Monat alt
TransMedics remains a Strong Buy after stellar growth, innovative technology, and founder-led leadership, with shares up 88% YTD, far outpacing the S&P 500. The company's unique OCS platform, integrated logistics, and service model create a strong moat, with next-gen products and international expansion as major growth catalysts. Financials are robust: Q2 2025 revenue grew 37.7% YoY, margins im...
Neutral
PRNewsWire
etwa ein Monat alt
ANDOVER, Mass. , Aug. 25, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences.
Neutral
Seeking Alpha
etwa ein Monat alt
TransMedics delivered another strong beat-and-raise quarter, but Q3 faces a likely seasonal slowdown that could disappoint optimistic investors. The long-term thesis remains robust: best-in-class preservation, logistics, and expansion into new organs and geographies support significant growth potential. Despite recent CEO insider buying, the purchase is negligible relative to his holdings, and ...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen